In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of treatment Tirzepatide users experienced greater waistline reduction (7. ...

“Even though drugs like tirzepatide and semaglutide work really well—better than anything we have ever seen—we still have people who don't respond to them,” said Dr. Aronne.

Researchers collected data from the five SURPASS trials, which assessed the effects of tirzepatide among people with type 2 diabetes. Tirzepatide was compared with placebo in SURPASS-1 and SURPASS ...

The current trial included a higher percentage of men (35%) than previous trials, especially when compared with the STEP trials involving persons without diabetes, in which 19 to 26% of the ...

The trial was run in the U.S., Argentina, Brazil, China, India, Japan, Mexico, Russia, and Taiwan. Each group lost weight on average over the course of 72 weeks, but the loss was much greater in ...

Topline results were announced from a phase 3b clinical trial comparing tirzepatide with semaglutide in obese or overweight participants without type 2 diabetes. The phase 3b SURMOUNT-5 study ...

Even though drugs like tirzepatide and semaglutide work really well, better than anything we have ever seen, we still have people who don't respond to them. So, moving forward, we want to keep ...

Injection site reactions were reported by 1.15% of the placebo group, 1.89% of the 5 mg tirzepatide group, 2.44% of the 10 mg tirzepatide group and 3.11% of the 15 mg tirzepatide group.

Preliminary data from a large Phase 3 clinical trial is offering promising signs for a new anti-obesity drug. Called tirzepatide, the drug helped overweight and obese participants lose up to 22.5 ...

The 'twincretin' tirzepatide (Mounjaro) met its primary endpoints compared with placebo in the SURMOUNT-2 trial, designed to test weight loss efficacy, in top-line results reported by Lilly.